| http://www.w3.org/ns/prov#value | - Until the discovery of aquaporin 4 antibodies (AQP4-Ab) in 2005,1 neuromyelitis optica (NMO) was defined clinically as the coexistence of inflammatory myelitis and optic neuritis without symptomatic disease outside of these regions.2 The high specificity of AQP4-Ab3- 5 has enabled broadening of the clinical phenotype of NMO; it has become clear that many patients have limited forms of disease such
|
